Establishing a relevant mouse model with susceptibility to non-adapted influenza viruses for vaccine challenge studies
建立对非适应性流感病毒易感的相关小鼠模型,用于疫苗攻击研究
基本信息
- 批准号:10211108
- 负责人:
- 金额:$ 22.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-06 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAnimalsAntibodiesAntibody titer measurementAntiviral AgentsAvian Influenza A VirusBody Weight decreasedCharacteristicsDefectDevelopmentDoseEngineeringGenesGeneticHealthHumanIFNAR1 geneImmuneImmune responseImmune systemImmunityImmunologic Deficiency SyndromesInfectionInfectious Disease ImmunologyInfluenza A virusInfluenza B VirusInfluenza vaccinationIntegral Membrane ProteinInterferonsKnockout MiceLibrariesMeasurableMeasuresModelingMusNON MouseNatural ImmunityOutcomePathogenicityPathologyPopulationPreclinical TestingPredispositionProteinsPublishingPulmonary PathologyResearchSCID MiceTechnologyTestingVaccinationVaccine ResearchVaccinesValidationViralVirulentVirusWeightWeights and MeasuresWild Type MouseWorkZoonosesadaptive immune responseadaptive immunitycost effectivegenetic associationimprovedin vivoinfluenza infectioninfluenza virus straininfluenza virus vaccineinfluenzavirusinsightmouse modelnovel vaccinespathogenic viruspre-clinicalresearch and developmentseasonal influenzaswine influenzauniversal influenza vaccinevaccine candidatevaccine developmentvaccine efficacyvaccine evaluation
项目摘要
SUMMARY
Influenza virus infection is a major health concern worldwide. Our best defense against seasonal influenza
virus infections is vaccination, but current vaccine strategies are not fully effective and may not offer protection
against viruses that emerge from animals. One impediment to the development of better vaccines is the lack of
a tractable and cost-effective small animal model for testing new vaccine technology. Mice are ubiquitously
used in research, but influenza viruses that infect humans often require adaptation in order to infect and cause
pathology in mice. This requirement for virus adaptation limits the utility of the mouse model for testing human
vaccine candidates in challenge studies with relevant non-adapated human viruses. However, we found that
mice engineered to lack a critical antiviral restriction factor known as interferon-induced transmembrane protein
3 (IFITM3) show increased susceptibility to a variety of influenza virus strains, including human isolates that
otherwise do not cause significant pathology in wild type mice. We propose that IFITM3 knockout mice may
thus serve as a long-sought mouse model for influenza virus vaccine testing. We will test whether these mice
possess the two characteristics needed in a pre-clinical testing model: 1) Whether IFITM3 knockout mice
possess the ability to mount protective adaptive immune responses upon vaccination, and 2) Whether IFITM3
knockout mice are fully susceptible to a wide breadth of human and animal-derived influenza viruses. In
addition to allowing more rapid and cost-effective testing of new seasonal and universal influenza virus
vaccines, this research will also provide insights into humans who possess IFITM3 defects in terms of virus
susceptibility and the ability to counteract this immunodeficiency with vaccination.
概括
流感病毒感染是全世界的一个主要健康问题。我们对抗季节性流感的最佳防御措施
病毒感染就是疫苗接种,但目前的疫苗策略并不完全有效,可能无法提供保护
对抗来自动物的病毒。开发更好疫苗的障碍之一是缺乏
用于测试新疫苗技术的易于处理且具有成本效益的小动物模型。老鼠无处不在
用于研究,但感染人类的流感病毒通常需要适应才能感染并引起
小鼠病理学。这种病毒适应的要求限制了小鼠模型用于测试人类的效用
与相关非适应性人类病毒进行挑战研究的候选疫苗。然而,我们发现
转基因小鼠缺乏一种关键的抗病毒限制因子,即干扰素诱导的跨膜蛋白
3 (IFITM3) 显示对多种流感病毒株的敏感性增加,包括人类分离株
否则不会在野生型小鼠中引起明显的病理变化。我们建议 IFITM3 敲除小鼠可能
因此可以作为流感病毒疫苗测试的长期寻找的小鼠模型。我们将测试这些老鼠是否
具备临床前测试模型所需的两个特征:1)是否为IFITM3基因敲除小鼠
具有在疫苗接种后产生保护性适应性免疫反应的能力,以及 2) IFITM3 是否
基因敲除小鼠对多种人类和动物源性流感病毒完全敏感。在
除了允许对新的季节性和通用流感病毒进行更快速和更具成本效益的检测之外
疫苗,这项研究还将深入了解具有 IFITM3 病毒缺陷的人类
易感性以及通过疫苗接种抵抗这种免疫缺陷的能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Yount其他文献
Jacob Yount的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacob Yount', 18)}}的其他基金
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10597869 - 财政年份:2023
- 资助金额:
$ 22.37万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10084253 - 财政年份:2017
- 资助金额:
$ 22.37万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10367235 - 财政年份:2017
- 资助金额:
$ 22.37万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10531244 - 财政年份:2017
- 资助金额:
$ 22.37万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
9288927 - 财政年份:2017
- 资助金额:
$ 22.37万 - 项目类别:
Molecular Control of IFITM3 in Restricting Influenza Virus Infection
IFITM3 在限制流感病毒感染中的分子控制
- 批准号:
9012283 - 财政年份:2015
- 资助金额:
$ 22.37万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应器的机制分析
- 批准号:
8601556 - 财政年份:2011
- 资助金额:
$ 22.37万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应器的机制分析
- 批准号:
8165228 - 财政年份:2011
- 资助金额:
$ 22.37万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应子的机制分析
- 批准号:
8623095 - 财政年份:2011
- 资助金额:
$ 22.37万 - 项目类别:
相似国自然基金
TLR4调控系统性红斑狼疮中自身反应性B-1a细胞活化的作用及机理研究
- 批准号:81901635
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
中东呼吸综合征新型人源应急救治单克隆抗体保护作用机制研究
- 批准号:81772191
- 批准年份:2017
- 资助金额:56.0 万元
- 项目类别:面上项目
IL-17促进系统性红斑狼疮发病中浆细胞功能的机制研究
- 批准号:81771761
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
肺腺癌中Timp-1促癌机制的研究及其阻断抗体的运用
- 批准号:81672268
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
抗磷脂抗体诱导中性粒细胞释放NETs致抗磷脂综合征肾病的机制研究
- 批准号:81671589
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases
代谢性疾病的产后和产前治疗碱基编辑
- 批准号:
10668614 - 财政年份:2023
- 资助金额:
$ 22.37万 - 项目类别:
Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation
志贺氏菌结合疫苗 (SCV4) 的开发、表征和临床前评估
- 批准号:
10704325 - 财政年份:2023
- 资助金额:
$ 22.37万 - 项目类别:
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV
一种基于免疫优势的泛肺炎病毒疫苗,用于预防 RSV 和 hMPV
- 批准号:
10735979 - 财政年份:2023
- 资助金额:
$ 22.37万 - 项目类别: